Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Actuate Therapeutics Inc's Competitiveness

Name: Actuate Therapeutics Inc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Actuate Therapeutics Inc (ACTU) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/ACTU/competitors                    

                        https://api.csimarket.com/api/v1/companies/ACTU/relationships                    

                        https://api.csimarket.com/api/v1/companies/ACTU/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Actuate Therapeutics Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Actuate Therapeutics Inc	-	-	-	Yes
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

ACTU Stock Performance relative to its Competitors

ACTU Competitors (weighted) Percent change over the selected range

Actuate Therapeutics Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

Similar-Size
(1 of 10)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Actuate Therapeutics Inc	-89.40 %	Underperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (0)	40.4%	63.2%
Similar-Size Competitors (10)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Actuate Therapeutics Inc's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

ACTU Stock Performance relative to Similar-Size Competitors

ACTU Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Actuate Therapeutics Inc's Comment on Competition and Industry Peers

The company operates in the biotechnology and pharmaceutical industries, focusing on oncology. It faces competition from major pharmaceutical and biotechnology firms, academic institutions, government agencies, and public and private research organizations. Its leading clinical asset, Elraglusib Injection ("elraglusib"), is in a Phase 2 clinical trial as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). Current standard first-line treatments for mPDAC include GnP, FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin), and NALIRIFOX (liposomal irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin), which offer modest overall survival benefits. The company is developing elraglusib in combination with GnP. Competitors target pathways such as KRAS, which intersect with GSK-3 pathways, indicating potential for combination therapies with elraglusib. The company recognizes competitors conducting clinical trials or marketing in anticipated regions, as well as other companies, including smaller or early-stage firms and academic and research institutions, as significant competitors.

Competitor data is not yet available for Actuate Therapeutics Inc.

Actuate Therapeutics Inc's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
pembrolizumab	Named by the company	85%	2022 to 2026	3
Lynparza	Named by the company	85%	2022 to 2026	3
olaparib	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Actuate Therapeutics Inc's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.